Tiedje, Dorothee
Borowski, Matthias
Simbrich, Alexandra
Schlößler, Kathrin
Kruse, Klaus
Bothe, Christiane
Kuss, Katrin
Adarkwah, Charles Christian
Maisel, Peter
Jendyk, Ralf
Kurosinski, Marc-André
Gerß, Joachim
Tschuschke, Christian
Becker, Ralf
Roobol, Monique J.
Bangma, Chris H.
Hense, Hans-Werner
Donner-Banzhoff, Norbert
Semjonow, Axel
Funding for this research was provided by:
Deutsche Krebshilfe (109905)
Westfälische Wilhelms-Universität Münster
Article History
Received: 12 April 2021
Accepted: 10 November 2021
First Online: 6 December 2021
Competing interests
: N.D.B. is co-chairman of the Association for Patient-orientated Communication (GPZK), a non-profit organisation distributing decision-support software, among these the PSA decision aid investigated in this study. He does not obtain a salary or other personal income from GPZK. A.Se reports grants from German Cancer Aid, during the conduct of the study; other from Myriad, from Philips Healthcare, from Proteomedix, personal fees from Janssen, personal fees from Ipsen, outside the submitted work. In addition A.Se has a patent Characterization of primary tumors (039PCT0735) issued. D.T. reports personal fees from Novartis, outside the submitted work. M.B., A.Si, K.S., K.Kr, C.B., K.Ku, C.C.A., P.M., R.J., M.A.K., J.G., C.T., R.B., M.J.R., C.H.B and H.W.H declare no conflicts of interests.